To dissect the mechanisms of resistance, we previously developed a culture model with a blast crisis CML cell line that recapitulates clinical CML acquired resistance through BCR-ABL mutations [4]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.